Colorectal Cancer Clocks in on TIME

Overview

Journal Nat Immunol

Date 2024 Jun 12

PMID 38866973

Authors

Amelia M Knudsen-Clark

Brian J Altman

Affiliations

Soon will be listed here.

References

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Chun S, Fortin B, Fellows R, Habowski A, Verlande A, Song W . Disruption of the circadian clock drives loss of heterozygosity to accelerate colorectal cancer. Sci Adv. 2022; 8(32):eabo2389. PMC: 9365282. DOI: 10.1126/sciadv.abo2389. View

Man K, Loudon A, Chawla A . Immunity around the clock. Science. 2016; 354(6315):999-1003. PMC: 5247264. DOI: 10.1126/science.aah4966. View

Fortin B, Pfeiffer S, Insua-Rodriguez J, Alshetaiwi H, Moshensky A, Song W . Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. Nat Immunol. 2024; 25(7):1257-1269. PMC: 11374317. DOI: 10.1038/s41590-024-01859-0. View

Aiello I, Mul Fedele M, Roman F, Marpegan L, Caldart C, Chiesa J . Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation. Sci Adv. 2020; 6(42). PMC: 7556830. DOI: 10.1126/sciadv.aaz4530. View

Hadadi E, Taylor W, Li X, Aslan Y, Villote M, Riviere J . Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice. Nat Commun. 2020; 11(1):3193. PMC: 7314789. DOI: 10.1038/s41467-020-16890-6. View

Wang C, Barnoud C, Cenerenti M, Sun M, Caffa I, Kizil B . Dendritic cells direct circadian anti-tumour immune responses. Nature. 2022; 614(7946):136-143. PMC: 9891997. DOI: 10.1038/s41586-022-05605-0. View

Qian D, Kleber T, Brammer B, Xu K, Switchenko J, Janopaul-Naylor J . Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021; 22(12):1777-1786. DOI: 10.1016/S1470-2045(21)00546-5. View

Lasser S, Ozbay Kurt F, Arkhypov I, Utikal J, Umansky V . Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol. 2024; 21(2):147-164. DOI: 10.1038/s41571-023-00846-y. View

10.

Tsuruta A, Shiiba Y, Matsunaga N, Fujimoto M, Yoshida Y, Koyanagi S . Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice. Mol Cancer Res. 2022; 20(6):972-982. PMC: 9381128. DOI: 10.1158/1541-7786.MCR-21-0786. View

11.

Yeung C, Kartolo A, Tong J, Hopman W, Baetz T . Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma. Immunotherapy. 2023; 15(11):819-826. DOI: 10.2217/imt-2022-0139. View

12.

Karaboue A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E . Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers (Basel). 2022; 14(4). PMC: 8870559. DOI: 10.3390/cancers14040896. View